The European Commission has authorized Rasonque, a tablet treatment for an aggressive but common form of pancreatic cancer. In its clinical trial, 76.6% of patients were alive one year after starting treatment, compared with 40–45% receiving chemotherapy alone.

Developed by the American startup Revolution Medicines, the drug uses a new molecule called daraxonrasib. Patients must meet several eligibility criteria, including having received previous treatment. The authorization therefore does not cover everyone with pancreatic cancer.

The European decision, announced Wednesday, follows approval by the US Food and Drug Administration in late August. Regulators on both sides of the Atlantic gave the treatment priority review. The European Medicines Agency, or EMA, had classified it as “high priority” because of the limited treatment options for the disease.

The trial results show a substantial advantage over standard chemotherapy. Half of the patients who received Rasonque survived more than 13 months, twice as long as those in the chemotherapy group. Tumor growth stopped in 90% of patients, while tumors shrank or disappeared in slightly more than 60%.

The disease kills approximately 490,000 people worldwide each year, according to the Global Cancer Observatory. France’s Fondation ARC pour la recherche sur le cancer puts five-year survival at just 11%. That figure describes the disease’s prognosis; it is not a measure of the new drug’s long-term results.

Dr. Wungki Park, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center in New York, described the results as “the closest thing to a cure.” Michelle Mitchell, chief executive of Cancer Research UK, called the treatment “the biggest advance we have seen in decades for patients with pancreatic cancer.”

Rasonque is not, however, an established cure. Its demonstrated contribution is to halt or reverse tumor growth and extend survival for previously treated patients facing a disease with few treatment options.